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ABSTRACT 
Classical Hodgkin Lymphoma is a germinal center B cell malignancy. Over the past 40 years, through greater 
understanding of disease pathogenesis, advancements in treatment have lead to greater than 80% long-term 
survival rates after standard first line therapy.1 Currently, first-line management of the disease varies, most 
commonly involving the use of a standard chemotherapy regime (i.e. ABVD or BEACOPP), with or without the 
use of additional chemotherapies or involved-field radiation therapy.2 Treatment selection is influenced by 
disease staging at diagnosis and the need to maintain therapeutic efficacy, whilst minimising the risk of late 
and potentially fatal therapy-associated side effects.2 Consequently, higher than acceptable drug-associated 
toxicities and patient relapse represent the future challenges of this disease. Novel therapies, targeting the 
aberrant signalling pathways and phenotypic features of the malignant cell pool, and its associated 
inflammatory infiltrate, are the future direction of disease management. Currently, combination therapies 
targeting the PI3K/Akt/mTOR pathway and transcription modulation have shown the greatest clinical efficacy 
in improving survival outcomes in previously heavily treated cHL patients, with minimal side effects. Whilst 
these therapies do not yet achieve the clinical efficacy of first line therapies, preliminary stage I and II trials have 
demonstrated a reduction in drug associated toxicities and side effects relative to existing treatments for 
relapse. This paper will investigate current understanding of the pathogenesis of cHL, and how this has shaped 
the targets of novel therapies for the disease.  
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Introduction 
Adaptive immunity consists of a population of 
lymphocytes, which confer highly specific and long 
lasting immunity against pathogenic agents.4 The 
immune response generated can be classified as 
either humoral or cell mediated, and serves to 
eliminate pathogens from the body.4 When the 
normal processes that drive the development, 
differentiation or activation of these lymphocytes 
become distorted, pathologies of the immune 
system may result.  
 
Approximately 95% of all lymphomas are of B cell 
origin. This includes Hodgkin lymphoma (HL), which 
accounts for 0.6% of newly diagnosed cancer cases 
each year and is attributed to 0.5% of all deaths due 
to cancer.3,5,6 The disease is associated with 
characteristic B symptoms, which include night 
sweats, fever (>38°C), and weight loss (>10%) over 
a 6 month period.7 The disease represents 11% of 
all B cell malignancies, and is considered relatively 
curable, owing to recent advancements in anti-
tumour combination chemotherapies and involved-
field radiation therapy (IFRT).6,8  
 
HL can be further subdivided into classical (cHL) or 
nodular lymphocyte predominant. The former is 
characterised by the presence of mono- (Hodgkin) 
or multinucleated (Reed-Sternberg) neoplastic cells 
termed Hodgkin Reed-Sternberg (HRS) cells.9 With 
a bimodal age distribution of occurrence, the 
pathogenic mechanisms leading to development of 
cHL are thought to include both environmental and 
genetic factors, with a strong association with 
Epstein Barr virus (EBV) co-infection and human 
leukocyte antigen (HLA) genotypes I and III.9,10 
Tumour composition and progression is remarkably 
consistent between individual cases of cHL, a factor 
that has contributed to the success of current 
therapies.11,12  
 
Whilst these therapies have shown great clinical 
efficacy, higher than acceptable drug-associated 
toxicities and patient relapses represent the current 
clinical challenges of the disease. In recent years, 
fluorine-18 fluorodeoxyglucose positron emission 
tomography (18F-FDG-PET) has been used to tailor 
first and second line therapies for cHL patients. 18F-
FDG-PET has shown considerable potential in 
improving clinical outcomes, sparing low-risk 
patients from overly aggressive treatments and 
accurately identifying high-risk patients whom may 
benefit from changes to standard therapy.13 Further 
research is, however, required to better define what 
constitutes a positive or negative scan, elucidate the 
factors which influence tracer uptake, and determine 
the optimal timing for when such scans should be 
performed.13 Increased risk of secondary neoplasms, 
cardiovascular and pulmonary disease, are other 
clinical challenges faced in the management of 
long-term survivors of cHL.7 Whilst advancements in 
radiotherapy, which have led to a reduction in the 
number of cycles and intensity of combination 
chemotherapies required, have been linked to a 
slight decline in risk of secondary malignancies, 
death from non-HL disease is still greater in this 
cohort relative to the general population.7,14 
Following from this, the advent of new therapies and 
ongoing clinical trials has further emphasised the 
need for long-term follow up in cHL patients, to 
assess drug efficacy and late developing side 
effects. Finally, poor prognosis and death due to 
non-HL disease is a current challenge faced by older 
cHL patients.7 Relative to their younger 
counterparts, older cHL patients have been 
associated with an increased number of 
comorbidities and an inability to tolerate intensive 
treatment regimes, making delivery of first line 
therapies difficult.7 Future treatment strategies must 
look towards addressing the issues surrounding 
current therapy intensity and side effects to improve 
outcomes for patients.   
 
This review investigates how our current 
understanding of the pathogenesis of cHL is 
shaping the targets for future therapies, which aim 
to combat the clinical challenges raised by current 
disease management. Current therapy targets and 
efficacy will be considered in contrasts to novel 
therapies, their modality, side effects and expected 
efficacy. 
 
Methods 
Information for this paper was collected using the 
PubMed and UpToDate databases. Papers were 
selected based on relevance, using a combination 
of the search terms; Hodgkin lymphoma, classical 
Hodgkin lymphoma, pathogenesis, treatment and 
current therapies. Any therapies found by this 
search, were then searched for directly using the 
drug name. Data with respect to non-Hodgkin 
lymphoma was excluded. Articles referencing data 
specific to classical Hodgkin lymphoma was 
included. A total of 42 papers were collected for 
use, from June 2014 to June 2015, with papers 
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selected post 2009 for novel therapies and post 
1995 for those regarding pathogenesis of cHL.  
 
Pathogenesis of Classical Hodgkin 
Lymphoma 
B cell lymphomas are characterised by their 
phenotypic resemblance to features of normal B 
cells during development. In the case of cHL, HRS 
cells are thought to be derived from a pool of pre-
apoptotic germinal center B cells, which have lost 
the capacity to express B cell receptor.6 For a given 
case of cHL, studies of the HRS cell population 
indicate identical immunoglobulin (Ig) gene 
rearrangement and somatic hypermutation, 
implicating the clonal expansion of a malignant cell 
population of mature, post germinal center origin.9 
Set upon a non-malignant, inflammatory 
background of lymphocyte infiltrate, HRS cells 
exhibit distinct features including a lack of B cell 
receptor and positivity for phenotypic markers such 
as TARC, CD15, Pax-5, MUM-1, CD138 and CD30.15 
The lymphocyte infiltrate and expression of these 
specific surface receptors promotes the survival of 
this neoplastic cell population through paracrine 
signalling and immune suppression of anti-tumour 
responses.  
 
The disease is also characterised by its links with 
environmental and genetic factors. Associated with 
one-third of all diagnosed cases of cHL in the 
developed world, EBV gene expression is thought 
to promote B cell survival, transformation and 
reprogramming towards a HRS cell phenotype.9 
Following primary infection, EBV becomes latent in 
the host memory B cell population, such that it can 
persist for the lifetime of the cell. EBV encoded 
EBNA-1 and LMP-1 gene products are thought to 
be essential for the transformation of memory B 
cells.9 These gene products act on intracellular 
signalling pathways, where EBNA-1 acts directly to 
down regulate tumour-suppressor gene expression, 
as well as supporting tumour development through 
up-regulation of CCL22, which promotes T 
regulatory cell activation.5 Similarly, LMP-1 gene 
product mimics the signal conferred by CD40, which 
acts downstream to activate NF-κB, p38, PI3K, AP1, 
and JAK-STAT signalling to promote cell 
survival.16,17 Genetic studies have also shown that 
crippling mutations in Ig genes, which encode the B 
cell receptor, are almost exclusively associated with 
EBV positive cases of cHL. This link is thought to be 
related to the EBV encoded gene LMP-2, which 
appears to reprogram mature B cells towards a HRS 
cell phenotype, promoting the rescue of germinal 
center B cells, lacking a B cell receptor, from 
apoptosis.9  
 
The bimodal age distribution observed in cHL is 
supported by the delayed exposure theory.18 This 
theory links socioeconomic status to delayed 
childhood exposure to common pathogens, such as 
EBV, which has been associated HL development in 
young adults.18 Epidemiological studies have linked 
increased risk of HL development in young adults to 
high maternal education, small sibship size, low 
housing density, and other correlates of high 
socioeconomic status.18-20 These factors are thought 
to delay exposure to common childhood infections, 
and result in increased severity of disease upon 
exposure in later life.18 In the case of EBV exposure 
and cHL, high socioeconomic status has been linked 
to increased risk of developing EBV-positive cHL in 
adolescence (15-39 years), whereas late onset cHL 
(55-79 years) is typically EBV-negative and 
associated with lower socioeconomic status.18 
 
A strong correlation exists between EBV-associated 
cHL and particular HLA genotypes.10 Cytotoxic T 
lymphocytes (CTLs) play a crucial role in the 
management of EBV infections, where their 
response is dependent on antigen presentation by 
HLA’s on antigen presenting cells. Association 
studies have identified areas within HLA class I and 
class III regions of the genome, in particular alleles 
126 and 284 of micro-satellite markers D6S265 and 
D6S510 respectively, which are linked to increased 
susceptibility to cHL.10 Specifically, these regions of 
variance have been linked to EBV positive cases of 
cHL, suggesting that HLA mediated antigen 
presentation plays a crucial role in the pathogenesis 
of the disease. It is thought that in susceptible 
individuals, the weakened CTL response enables 
enhanced expansion of EBV-infected cells, with 
elevated titres of the virus promoting B cell 
transformation.9 
 
After transformation, survival of the HRS cell 
population is dependent on the dysregulation of the 
cell fate through an inflammatory response which 
modulates a family of transcription factors, nuclear 
factor (NF)-κB, that enable the evasion of apoptotic 
pathways. Under normal conditions, NF-κB is 
present in an inactive state in the cell cytoplasm, 
transiently activated under the tight control of 
stimulatory signals. In the HRS cell population, NF-
κB becomes inappropriately activated to confer cell 
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survival and proliferation signals. This inappropriate 
activation is thought to be the consequence of EBV 
virus LMP-1 gene expression, which confers intrinsic 
signals for the up regulation of NF-κB in EBV 
positive tumours.9 Alternatively, in EBV negative 
instances of cHL, over expression of cell surface 
receptors (CD30), acquisition of deleterious 
mutations (in A20) or loss of regulatory proteins 
(IκB), promote the sustained signalling of NF-κB.9 
NF-κB activation confers a ‘rescue’ signal to 
germinal center B cells that are destined for 
apoptosis, due to their inability to express a B cell 
receptor. As this cell population persists, the cells 
undergo uncontrolled clonal expansion, acquiring 
additional mutations, which drive them towards the 
malignant HRS cell phenotype. The HRS cells then 
secrete a milieu of cytokines, which promote the 
accumulation of the non-malignant inflammatory 
infiltrate characteristic of cHL. Together, this 
tumorous mass forms an environment conducive to 
the continued survival of the HRS clone.  
 
Diagnosis and staging of classical Hodgkin 
Lymphoma 
The diagnosis and staging of cHL is crucial to the 
management and treatment of the disease. 
Identified by the presence of HRS cells, the disease 
is most commonly diagnosed via light microscopy 
and immunohistochemistry of tissue biopsies 
exhibiting lymphadenopathy, preferably through 
obtaining an entire lymph node from the affected 
region.21 Once a cHL diagnosis has been confirmed, 
staging tests are conducted to determine the extent 
of disease. Previously, bone marrow biopsy was a 
necessary component of staging, however recent 
utilisation of non-invasive whole body imaging 
procedures, such as computed tomography (CT) 
and positron emission tomography (PET) scans, 
allow the clinical staging of cHL with no detrimental 
impact on patient treatment or outcomes.22 Along 
with imaging, laboratory studies are also conducted 
to assist in the determination of the optimal course 
of therapy. These tests include complete blood 
count, absolute lymphocyte count, erythrocyte 
sedimentation rate, HIV serology, pregnancy test in 
women of childbearing age and liver, bone, and 
renal function biochemical tests. 
 
Currently, clinical staging of cHL adopts the 
Cotswold-modified Ann Arbor classification system, 
which considers the number of sites involved, type 
of tissue involvement (nodal versus extranodal) and 
the distribution of disease (See Table 1).23 This 
staging method identifies patients as either early 
(Stage I and II) or advanced (Stage III and IV) stage 
disease. Early stage disease can be further stratified 
based of the presence or absence of certain 
prognostic features, which also influence the 
treatment strategy adopted.7 This stratification is 
termed favourable or non-favourable disease 
prognosis and has been defined by the German 
Hodgkin Study Group (GHSG) and the European 
Organisation for the Research and Treatment of 
Cancer (EORTC) (See Table 2).7  
 
Table 1: Cotswold-modified Ann Arbor 
Classification (23) 
Stage Tissue Involvement 
I Single lymph node region (I) or one 
extralymphatic site (IE) 
II Two or more lymph node regions, same 
side of the diaphragm (II) or contiguous 
extralymphatic extension plus one or 
more lymph node regions same side of 
the diaphragm (IIE) 
III Lymph node regions on both sides of the 
diaphragm (III), which may be 
accompanied by contiguous 
extralymphatic extension (EIII)  
IV Diffuse involvement of one or more 
extralymphatic organs or sites 
Suffix Features 
A No B symptoms 
B Presence of at least one of the following: 
unexplained weight loss >10% of baseline 
during a 6 month period prior to staging; 
recurrent unexplained fever >38°C; 
recurrent night sweats 
X Bulky tumor is defined as either a single 
mass of tumour tissue exceeding 10cm in 
largest diameter or a mediastinal mass 
exceeding one-third of the maximum 
transverse transthoracic diameter 
measured on a standard posterior-anterior 
chest radiograph.  
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Table 2: Comparison of the Prognostic Factors for 
the Determination of Early Stage Disease in 
classical HL (7) 
Prognostic 
Factors 
Favourable Early 
Stage Prognosis 
Unfavourable 
Early Stage 
Prognosis 
GHSG EORTC GHSG EORTC 
Large 
Mediastinal 
Adenopathy 
✗ ✗ ✓ ✓ 
ERS <50, 
without B 
symptoms 
✓ ✓ ✗ ✗ 
ERS <30, 
with B 
symptoms 
✓ ✓ ✗ ✗ 
Extranodal 
Disease or 
Age 
✗ ≤ 50 
years 
✓ > 50 
years 
Number of 
lymph node 
sites 
involved 
1-2  1-3  ≥3  ≥4  
 
For patients with advanced stage disease, risk 
stratification tools can be useful to identify patients 
at risk of standard treatment failure and who may 
benefit from a modified or intensified treatment 
regime.24 The International Prognostic Index (IPI) is 
the most widely used scoring system, which predicts 
5-year freedom from progression and overall 
survival rate.24,25 However, whilst the IPI is widely 
used, its lack of consideration for advancements in 
treatment has meant it is yet to be proven useful for 
the determination for initial therapy in disease.     
 
Current treatment of Classical Hodgkin 
Lymphoma 
As stated previously, the clinical staging and 
prognostic features for a given case of cHL largely 
influences treatment selection and management 
strategy for patients. Standard first line therapy for 
early stage favourable cHL involves 2 cycles of 
ABVD (adriamycin, bleomycin, vinblastine and 
dacarbazine) chemotherapy in combination with 20 
Gy IFRT.7 Emerging evidence suggests that PET 
scans may be used to tailor treatment therapies and 
reduce treatment intensity through omission of 
IFRT.13 However, research in this area is ongoing, 
with some finding that whilst initial outcomes are 
similar in early PET-negative patients opting for or 
against IFRT, the risk of early relapse is significantly 
higher in those who omitted irradiation.26 
Conversely, early stage unfavourable cHL requires 4 
cycles of ABVD chemotherapy in combination with 
30 Gy IFRT.3 For patients with advanced stage cHL, 
6-8 cycles of ABVD or 6 cycles of escalated 
BEACOPP (bleomycin, etoposide, adriamycin, 
cyclophosphamide, vincristine, procarbazine and 
prednisone) are recommended as the first line 
therapy.7 Studies comparing the efficacy of 
combination chemotherapies, ABVD and 
BEACOPP, in advanced stage cHL, have identified 
that whilst escalated BEACOPP is associated with 
improved initial tumour control, it is also linked to 
increase rates of fatal acute toxicities and secondary 
leukaemia.7,27 Furthermore, BEACOPP based 
therapy are associated with increased risk of direct 
side effects of chemotherapy, infectious 
complications, blood product requirements, 
infertility and the development of secondary acute 
myeloid leukaemia.7 As the long-term outcomes for 
both treatment options are similar, therapy selection 
is often influenced by patient preference with 
regards to the balance between drug efficacy and 
toxicity.  
 
After first line therapy, approximately 80% of cHL 
patients achieve long-term remission.1 However, 
within this population, drug-associated toxicities 
result in an increased mortality rate relative to the 
general population. Secondary neoplasms and 
cardiovascular disease represent the two major 
causes of non-relapse associated mortality for long-
term survivors of cHL.7 These outcomes are often 
associated with increased combination therapies 
involving IFRT, which may result in long-term 
anergic immunological responses and T cell 
defects.7 Pulmonary toxicity is another major side 
effect of bleomycin-containing chemotherapies, 
with outcomes ranging from reduction in diffusion 
capacity, lung volume and vital capacity to 
pneumonitis and end-stage pulmonary fibrosis.7 
Studies have demonstrated that 1-2% of bleomycin 
treated patients experience fatal pulmonary 
fibrosis.7 Psychological problems have also been 
associated with this cohort, owing to therapy-
induced infertility and reduction in quality of life.7  
 
For the remaining 20%, disease relapse and 
progression is by far the major cause of death after 
first line therapy.7 High-dose chemotherapy and 
autologous stem cell transplantation (SCT) 
represent the standard second-line treatment for 
refractory or relapsed cHL.28 Of those to receive 
second-line treatment, approximately 50% of 
relapsed patients and a minority of refractory 
Res Medica 2015, Volume 23, Issue 1 
	   52	  
patients will go on to achieve durable responses.28 
At present, allogeneic SCT represents the only 
strategy with curative potential for those remaining 
patients, however treatment has been associated 
with high mortality rate, due to resultant graft versus 
host disease or fatal infection post transplantation.28 
Whilst 18F-FDG-PET has been beneficial in 
identifying patients in whom allogeneic SCT is 
expected to have the greatest effect, overall survival 
(40-85%) and progression free survival (23-40%) 
remains low.13,28 In addition, the prognosis of 
patients who fail high dose chemotherapy and 
autologous SCT is poor.28 Therefore, novel 
therapies are needed to minimise current 
combination therapy associated toxicities and 
improve patient outcomes in the primary resistant 
and relapsed populations of cHL.28 
 
Future direction of therapies for classical 
Hodgkin Lymphoma 
The future direction of cHL treatment looks towards 
agents that are highly specific for the neoplastic HRS 
cell population and their characteristic non-
neoplastic inflammatory infiltrate 
microenvironment. Advancements in genomic 
sequencing have allowed for the identification of 
numerous aberrant signalling pathways specific to 
HRS cells and their microenvironment, which 
present potential targets for small-molecule 
therapies.11 These therapies aim to diminish the 
prosurvival signals and anti-apoptotic pathways 
conferred by the inflammatory infiltrate present in 
cHL, as well as target HRS cells by radiation-emitting 
immune conjugates.12 Since 1977, Brentuximab 
vedotin has been the only new therapy approved by 
the Food and Drug Administration for the treatment 
of cHL, illustrating the stark need for further research 
in this area.11 Ongoing clinical trials, examining the 
efficacy of immunotherapies and small-molecule 
therapies targeting oncogenic signalling pathways, 
appear promising (See Figure 1).29-33 
 
 
 
Immunotherapies 
Brentuximab vedotin, the most successful 
immunotherapy to date, is an antibody-drug 
conjugate, targeted against the CD30+ HRS cells 
pathognomonic of cHL.32 Associated with minimal 
severe adverse side effects, Brentuximab is currently 
used in the treatment of relapsed or refractory cHL 
patients, with phase I and II clinical trials 
demonstrating an overall response rate of 75% and 
complete remission in 34% of patients.32,34 Since 
then, various other monoclonal antibody therapies 
have entered clinical trials for the treatment of cHL. 
Whilst CD20 is not constitutively present on HRS 
cells, anti-CD20 therapies such as rituximab are 
used to target the inflammatory constituents of the 
microenvironment. The rational for targeting CD20 
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Figure 1. Phase I and Phase II clinical trials using current and novel therapies in the treatment of patients with 
relapsed or refractory cHL.  
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is to eliminate cells such as tumour-supportive 
reactive B cells and putative HL-initiating cells, 
which are CD20 positive and confer pro-survival and 
progression signals to HRS cells.12 Phase II clinical 
trials have demonstrated an overall survival rate of 
96-98% for newly diagnosed patients treated with 
rituximab in combination with ABVD chemotherapy, 
relative to the 94% achieved by ABVD alone.35,36 In 
addition, other monoclonal antibody therapies 
targeting the reactive inflammatory 
microenvironment observed in cHL have been 
developed. Alemtuzumab and Nivolumab are 
monoclonal antibodies against CD52 and PD1 
respectively, which target the T cell contingent of 
the characteristic inflammatory infiltrate of cHL. 
These drugs act to either dampen the T cell 
response by antibody mediated lysis or alternatively 
enhance the anti-tumour response through 
improved T cell receptor signalling.11,12  
Comparative clinical trials for these drugs in cHL 
patients are limited, however, preliminary data for 
Nivolumab is promising, with its use in relapsed or 
refractory HL patients achieving a response rate of 
87% and complete remission in 17% of patient.37 
 
Antibody mediated immunotherapies have shown 
efficacy in clinical trials, however, they are limited by 
their short half-life and need for repeat infusions. For 
this reason, interest has shifted towards adoptive 
immunotherapies to generate host directed, 
memory responses against tumour cells. Whilst 
weakly immunogenic, EBV latent membrane 
proteins, LMP1 and LMP2, have proved attractive 
targets for immunotherapy via EVB-specific CTLs in 
recent clinical studies on patients with EBV positive 
HL. These trials have shown that EBV-specific CTLs 
are generally well tolerated in patients post infusion, 
demonstrating biological activity and the capacity to 
induce complete or partial remission in patients with 
heavily pre-treated cHL.38 The benefit of EBV-
specific CTL adoptive immunotherapies is the 
potential for the generation of a memory T cell pool, 
conferring long-lived immunity, with minimal 
toxicities that do not eliminate healthy tissues.39 
However, whilst high cure-rates are achievable, 
results are not consistent and treatment is limited by 
the ability to expand sufficient autologous CTLs 
from heavily pre-treated patients with relapsed 
disease.39 In addition, the ability to generate a long-
lived memory response has proven difficult owing to 
the weakly immunogenic nature of LMP1 and LMP2, 
and the tendency of tumour cells to modulate the 
expression of targeted antigen to enhance survival. 
Research is currently under way investigating 
combination EBV-specific CTLs targeting both 
LMP1 and LMP2, demonstrating improved results.39    
 
Small Molecule Therapies 
Alternatively, to immunotherapies, further 
advancements and understanding into the 
oncogenic signalling pathways, which sustain the 
neoplastic cell population of cHL, have allowed for 
the development of new small molecule therapies. 
Studies have shown, the JAK/STAT, NF-κB, PI3K 
and MEK/ERK pathways are all constitutively active 
in HRS cells, conferring pro-survival, metabolism 
and immunity signals.11,33 Current clinical interest is 
focused on the PI3K/Akt/mTOR pathway, which 
contributes to the constitutive activation of NF-κB.33 
Everolimus and Temsirolimus are two analogues of 
rapamycin, which serve as mTOR inhibitors, and are 
currently undergoing clinical trials. Everolimus acts 
to down regulate the activation of NF-κB, inhibiting 
the subsequent survival signals, whilst Temsirolimus 
induces cell cycle arrest.33 Clinical trials in patients 
with relapsed cHL treated with Everolimus observed 
an overall response rate of 42%, which was generally 
well tolerated patients, with most patients going off 
the trial due to disease progression rather than due 
to drug associated toxicities.11,33 Conversely, JAK 
and NF-κB inhibitors have proven to be theoretically 
viable treatment options for relapsed cHL, however 
preliminary trials have shown minimal to no clinical 
significance as of yet.11 The encouraging overall 
response rate and ability to induce stable disease 
make mTOR inhibitors the current leading therapy 
in oncogenic signalling pathway treatments for 
those with relapsed cHL.  
 
Another avenue currently being explored for the 
treatment of resistant and relapsed cHL is 
epigenetic therapies. Histone deacetylase (HDAC) 
inhibitors, such as Panobinostat, have demonstrated 
direct and indirect antitumour clinical activity. This 
group of drugs is thought to exert its effects through 
induction of cell-cycle arrest and apoptosis, 
Abbreviations: 
• JAK/STAT – Janus Kinase / Signal Transducer and 
Activators of Transcription 
• NF-κB – Nuclear Factor Kappa Beta 
• PI3K – Phosphatidylinositol-3 Kinase 
• MEK/ERK – Mitogen-activated Extracellular-signal 
regulated Kinase / Extracellular-signal Related 
Kinase 
• Akt – Protein Kinase B 
• mTOR – Mammalian Target of Rapamycin 
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inhibition of angiogenesis and promotion of an 
antitumour microenvironment and immune 
response.40 In vitro studies have demonstrated 
HDAC inhibitors modulate the activity of 
transcription factors to either down regulate the 
expression of chemokines such a TARC, disrupt PD1 
and PDL1 signalling, or up regulate the expression 
of OX40L, TNFα and IL-17 to promote an anti-
tumour microenvironment.40,41 Panobinostat is 
considered the most potent HDAC inhibitor against 
cHL, with the highest single agent activity due to its 
ability to target multiple cellular pathways.40 Recent 
Phase II clinical trials in relapsed cHL patients 
observed a reduction in tumour size of 74%, with 4% 
of patients achieving complete remission and 23% 
achieving partial remission.40 The drug is generally 
well tolerated, with studies reporting grade 1 to 2 
side effects, including diarrhea, nausea, vomiting, 
fatigue and haematological effects such as 
thrombocytopenia, anaemia and neutropenia.29  
 
The unselective nature of Panobinostat means it is 
capable of exerting its effects on a wide range of 
signalling pathways and effector molecules within 
malignant cells. For this reason, Panobinostat is also 
being considered as a potential therapy to improve 
the efficacy of other drugs in the treatment of cHL. 
Studies examining HDAC inhibitors in combination 
with other small molecule therapies have 
demonstrated a synergistic effect between the two 
types of drugs. Independently, Panobinostat and 
Everolimus demonstrate modest clinical activity as 
single agents in the treatment of refractory cHL. 
However, in a recent Phase I trial, the combination 
therapy of Panobinostat and Everolimus in relapsed 
classical HL generated an overall response rate of 
43%, with 15% achieving complete remission.30 The 
improved efficacy of these therapies in combination 
is attributed to the ability of these drugs to target 
multiple sites within a common signalling pathway. 
However, due to the multifactorial effect of the 
drugs in combination, additive toxicities are a 
concern in the progression of this therapy option.  
 
Finally, immunomodulation is an alternative 
therapeutic option for the treatment of cHL. 
Lenalidomide is an immunomodulatory drug, 
currently being investigated for its efficacy in cHL 
patients who have progressed past first line therapy. 
Whist the mechanism of action are incompletely 
understood, it is thought Lenalidomide causes 
direct induction of apoptosis and anti-angiogenesis 
in the neoplastic cell population, as well as 
activation of immune effector cells.42 Due to its 
multimodality, Lenalidomide is currently being 
investigated as a single-agent therapy for those who 
have failed conventional therapies.42 Clinical trials of 
oral daily lenalidomide have yielded clinical 
responses and disease stabilisation in heavily pre-
treated HL patients. The drug has also shown high 
patient tolerability, with the most common drug 
limiting toxicities including cytopenias, rash and 
hepatic toxicity.11 Lenalidomide appears to be a 
strong candidate for future therapies in patients with 
tumour resistance to conventional combination 
chemotherapies and offers minimal adverse effects.  
 
Conclusion 
The future direction of treatment for classical HL 
lies in targeted small molecule and 
immunotherapies, used in conjunction with existing 
treatment regimes, for the management of 
refractory and relapsed patients. Whilst novel 
therapies, such as Panobinostat and Everolimus 
combinations and Lenalidomide, have shown a 
relative reduction in drug-associated toxicities, 
their efficacy is yet to match that of existing 
treatments. Future research should look towards 
not only optimising the efficacy of novel therapies, 
but also consider the refinement and enhancement 
of existing prognostic tools and standard 
treatments. This will enable the customisation of 
cHL therapy for patients based on prognostic 
features, minimising overly aggressive treatments 
in good prognosis patients and accurately 
identifying poor-risk patients whom may benefit 
from changes to standard therapy. Future 
challenges will be met in achieving equivalent drug 
efficacy in novel therapies relative to those 
existing, and the refinement of existing prognostic 
tools to enable the individualised management of 
patients with cHL.    
	  
What is known already: What this study adds/ highlights: 
•   The pathogenesis and phenotypic 
markers of the classical Hodgkin 
lymphoma malignant cell population  
•   Identification of the gaps existing in the treatment of classical 
Hodgkin lymphoma 
•   Synthesis of current findings from ongoing clinical trials 
investigating novel therapies for the treatment of classical  
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•   Existing therapies; their targets, 
efficacy and side effects 
•   Evaluation of which therapies appear most efficacious 
•   Suggestion as to the future direction of treatment for classical 
Hodgkin lymphoma.  
•    
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